



167

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: **Keith D. ALLEN**

Group Art Unit: **1632**

Serial No.: **09/903,377**

Examiner: **Paras Jr., Peter**

Filed: **July 10, 2001**

Customer No. **26619**

Title: **Transgenic Mice Containing Chemokine Receptor 9A Gene Disruptions**

Docket/Order No. **R-365**

Date: **April 5, 2004**

*FEE
FOR
UTI*

AMENDMENT AND RESPONSE TO OFFICE ACTION

Commissioner for Patents
Mail Stop Non-Fee Amendments
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

In response to the Office Action mailed December 5, 2003 in connection with the above-identified application, Applicants request consideration of the following amendments and remarks.

It is believed that the claims are currently in condition for allowance, and notice to that effect is respectfully requested. The Commissioner is hereby authorized to charge any deficiency or credit any overpayment to Deposit Account No. 50-1271 under Order No. R-365.

Respectfully submitted,

Date: April 5, 2004

Kelly L. Quast

Kelly L. Quast, Reg. No. 52,141

Deltagen, Inc.
1031 Bing Street
San Carlos, CA 94070
(650) 569-5100

04/26/2004 KTURNER 0000003 501271 09903377

01 FC:2251 55.00 DA